Marinus Pharmaceuticals, Inc. Company profile
About Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals Inc is a United States-based biopharmaceutical company. The Company offers development and commercialization of medical drugs for the treatment of serious neurological and psychiatric disorders such as epilepsy, post-traumatic stress, and fragile-x syndrome. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Marinus Pharmaceuticals Inc revenues increased from $1.7M to $15.3M. Net loss applicable to common stockholders increased 29% to $98.8M. Revenues reflect Federal contract revenue increase from $1.7M to $6.4M. Higher net loss reflects Interest Income decrease of 84% to $80K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$2.80 to -$2.69.
Latest shares articles
![](https://img.capital.com/imgs/articles/384x2000x0/1350x880_-HP-_Newsquawk-light_1.png)
![Lloyds share price forecast: An attractive dividend stock?](https://img.capital.com/imgs/articles/384x2000x0/Hero-image-bank_1.png)
![Exterior of Infosys headquarters](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_2035197281_0_0.jpg)
![Tesla logo atop of a Tesla Dealership illuminated at night.](https://img.capital.com/imgs/articles/384x2000x0/shutterstock_1494516293_0.jpg)